Braveheart Bio, Inc. (NASDAQ:BRVE) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Analysts unanimously recommend buying Braveheart Bio: all five covering firms rate the stock positively, with an average 12-month price target of $45.25 versus its $27.44 opening price.
• Recent coverage includes buy ratings and price targets of $45–$48 from Goldman Sachs, Stifel Nicolaus and Jefferies, while Cantor Fitzgerald issued an overweight rating with a $40 target.
• Insider buying has been substantial: insiders purchased 8.75 million shares worth approximately $157.5 million over the past three months, including large purchases by a director and major shareholder at $18 per share.

Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the last year is $45.25.

Several equities research analysts have issued reports on the company. The Goldman Sachs Group began coverage on Braveheart Bio in a report on Monday. They set a "buy" rating and a $48.00 price objective on the stock. Wall Street Zen upgraded shares of Braveheart Bio to a "hold" rating in a research note on Saturday, August 15th. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a research note on Monday. They issued a "buy" rating and a $45.00 target price on the stock. Cantor Fitzgerald started coverage on Braveheart Bio in a report on Monday. They issued an "overweight" rating and a $40.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on Braveheart Bio in a report on Monday. They set a "buy" rating and a $48.00 target price on the stock.

Braveheart Bio Price Performance

Shares of NASDAQ BRVE opened at $27.44 on Monday. Braveheart Bio has a 1 year low of $24.61 and a 1 year high of $32.00.

Insider Activity

In other news, Director Christopher Viehbacher acquired 83,333 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,499,994.00. Following the completion of the purchase, the director directly owned 609,519 shares of the company's stock, valued at $10,971,342. This trade represents a 15.84% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Growth Opportunities F. Forbion acquired 1,920,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, with a total value of $34,560,000.00. Following the acquisition, the insider owned 11,640,546 shares of the company's stock, valued at $209,529,828. This trade represents a 19.75% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 over the last three months.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source